CN106366120A - 2-carbonyl butyric acid p-metoxybenzene formyl hydrazone diphenyl tin complex and preparation method and application thereof - Google Patents

2-carbonyl butyric acid p-metoxybenzene formyl hydrazone diphenyl tin complex and preparation method and application thereof Download PDF

Info

Publication number
CN106366120A
CN106366120A CN201610753673.3A CN201610753673A CN106366120A CN 106366120 A CN106366120 A CN 106366120A CN 201610753673 A CN201610753673 A CN 201610753673A CN 106366120 A CN106366120 A CN 106366120A
Authority
CN
China
Prior art keywords
coordination compound
alpha
ketobutyric acid
stannous phenide
hydrazone stannous
Prior art date
Application number
CN201610753673.3A
Other languages
Chinese (zh)
Other versions
CN106366120B (en
Inventor
谭宇星
蒋伍玖
张志坚
张复兴
邝代治
朱小明
庾江喜
Original Assignee
衡阳师范学院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 衡阳师范学院 filed Critical 衡阳师范学院
Priority to CN201610753673.3A priority Critical patent/CN106366120B/en
Publication of CN106366120A publication Critical patent/CN106366120A/en
Application granted granted Critical
Publication of CN106366120B publication Critical patent/CN106366120B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22Tin compounds
    • C07F7/2284Compounds with one or more Sn-N linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22Tin compounds
    • C07F7/2296Purification, stabilisation, isolation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

The invention discloses a 2-carbonyl butyric acid p-metoxybenzene formyl hydrazone diphenyl tin complex. The 2-carbonyl butyric acid p-metoxybenzene formyl hydrazone diphenyl tin complex has the structural formula (I) shown in the specification, wherein R is phenyl. The invention further discloses a preparation method of the 2-carbonyl butyric acid p-metoxybenzene formyl hydrazone diphenyl tin complex and application in preparation of anti-cancer drugs.

Description

A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide coordination compound and its preparation Methods and applications

Technical field

The present invention relates to a kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide coordination compound and preparation method thereof, with And this ALPHA-ketobutyric acid preparing the application in cancer therapy drug to methoxybenzoyl hydrazone stannous phenide coordination compound.

Background technology

Organotin is the metallo-organic compound that a class contains sn-c key.Researcher just noticed before very early The Anticancer Activity in vitro of organo-tin compound.The research of organotin (iv) antitumor activity of compound can trace back to nineteen twenty-nine. 1967, kanisawa etc. thought that stannic chloride is invalid to the primary tumor of mice and rat.But in 1972, brown found, By food or drug administration by injection, triphenyltin acetate ph3snoocch3The tumour growth of mice can be suppressed, and triphenyltin chloride Then can not.Between 1972 ~ 1977 years, the substantial amounts of organo-tin compound of Dutch scholar's research, but find no screening valency further The compound of value.They continue deeper into research, finally found that the tin compound of two organic group coordinations, such as tin-oxide (r2Sno), stannum hydroxide [ snr2(oh) x ] etc. have anti-tumor activity, and find out that they all contain or hydrolyze and can produce stannum oxygen Key.1986, crowe etc. was found that some organo-tin compounds have preferable active anticancer again, from this, resisted with regard to organotin The research of cancer activity becomes another extremely active focus after cisplatin.1989, American National anticancer research institute (national cancer institute) has carried out antitumor activity screening, result table to more than 2,000 kinds of organo-tin compounds Some organo-tin compounds bright have inhibitory action to p388 Lymphocytic leukemia.2002, gielen et al. was to organic The activity of stannum carboxylate compound has done comprehensive summing up, thinks that many organo-tin compounds have really preferably external after research Active anticancer.

Research shows, the organic group that organic tin atom connects and the part participating in being coordinated decide organo-tin compound Biological activity, select some to have the tin atom in organic ligand and the organotin of good biological activity in itself and be coordinated and cause The great interest of people.Acylhydrazone is by a class schiff alkali cpd of hydrazide kind compound modification, they Formed by aldehydes or ketones and hydrazides condensation, there is in molecule the of bonding similar with peptide bond, there is good biological activity, stronger joining Capability and various coordination mode, and have a wide range of applications at aspects such as medicine, pesticide, material and analytical reagents.Closely Nian Lai, both at home and abroad many research worker it is compared in terms of biological activity and in depth studies, research finds acylhydrazone class Compound has the various active such as anticancer, sterilization, antiinflammatory.Therefore, acylhydrazone class schiff aar ligand is combined with organotin it is intended to Obtain the higher noval chemical compound of biological activity, become people's research direction interested.

Chinese patent cn 102718794a discloses a kind of pair of acylhydrazone class schiff alkali stannous phenide coordination compound and its in system Application in standby Antilung gland cancer, colon cancer, the medicine of leukaemia.

Chinese patent cn 101851251a disclose a kind of dibutyl tin coordination compound of acylhydrazone class schiff aar ligand and its Application in preparation treatment hepatocarcinoma, adenocarcinoma of lung, breast carcinoma, carcinoma of prostate, colon cancer or early children's leukemic medicine of grain.

Document (journal of organometallic chemistry, 2014,75:83-91) is reported, organotin Acylhydrazone class schiff alkali coordination compound is thin to human colon cancer cell (hct-116), human lung adenocarcinoma cell (a549), human umblilical vein endothelial Born of the same parents (huvec) have compared with strong biological activity, and are better than carboplatin.

Document (journal of organometallic chemistry, 2013,724:23-31) is reported, series has Machine stannum acylhydrazone class schiff alkali coordination compound, organo-tin compound and acylhydrazone class schiff aar ligand are respectively to human lung adenocarcinoma cell (a549), the inhibitory action of the cancerous cell such as human colon cancer cell (hct-8), people in loop (hl-60).

Document (bioorganic & medicinal chemistry letters, 2015,25:4461- 4463) Report, the active anticancer to human liver cancer cell (huh-7) and human lung adenocarcinoma cell (a549) for multiple acylhydrazone class schiff aar ligands.

Document (journal of organometallic chemistry, 2016,864:48-58) is reported, two hydrocarbon Base stannum acylhydrazone class schiff alkali coordination compound is to human lung adenocarcinoma cell (a549), human cervical carcinoma cell (hela), human breast cancer cell (mcf-7) inhibitory action of cancerous cell such as.

It is to the experiment proved that the material with active anticancer based on acylhydrazone class schiff alkali organotin complex, the present invention selects Select and methoxybenzoyl hydrazine, 2-butanone acid are reacted under certain condition with diphenyl stannum dichloride, synthesis has obtained to people's lung Cancerous cell (h460), human liver cancer cell (hepg2) and human breast cancer cell (mcf7) have the coordination compound of certain inhibitory activity, are Exploitation cancer therapy drug provides new approach.

Content of the invention

The first object of the present invention there is provided a kind of ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound.

The second object of the present invention is to provide above-mentioned ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound system Preparation Method.

The third object of the present invention is to provide above-mentioned ALPHA-ketobutyric acid that methoxybenzoyl hydrazone stannous phenide coordination compound is existed Prepare the application in cancer therapy drug.

As a first aspect of the present invention a kind of ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound, be The coordination compound of structural formula (i)

(i)

Wherein r is phenyl.

The ALPHA-ketobutyric acid of the present invention to methoxybenzoyl hydrazone stannous phenide coordination compound through elementary analysiss, infrared spectrum, Nuclear magnetic resoance spectrum and x- ray single crystal diffraction structural analyses, result is as follows:

Elementary analysiss (c24h22n2o4Sn): value of calculation: c 55.13, h 4.25, n 5.38;Measured value: c 55.16, h 4.27, n 5.40.

ft-ir (kbr, ν/cm-1): 3448, 3047, 2964, 2929,1633, 1600, 1581, 1494, 1176, 1095, 846, 731, 684, 640, 603, 588, 513, 445, 422.

1h nmr (500 mhz, cdcl3, δ/ppm): 8.31 (d,j=8.7 hz, 2h), 7.80-7.82 (m, 4h), 7.45-7.46 (m, 6h), 7.01 (d,j=8.7 hz, 2h), 3.90 (s, 3h), 3.07-3.12 (q,j=7.5 hz, 2h), 1.30 (t,j=7.5 hz, 3h).

13c nmr (126 mhz, cdcl3, δ/ppm): 174.48, 163.53, 158.75, 136.15, 135.84, 131.36, 130.79, 129.36, 124.59, 113.87, 55.51, 21.09, 10.66.

119sn nmr (187 mhz, cdcl3, δ/ppm): -294.23.

The ALPHA-ketobutyric acid of the present invention is crystal structure to methoxybenzoyl hydrazone stannous phenide coordination compound, and its crystal is just Hand over crystallographic system, space group p2 (1) 2 (1) 2 (1), a=0.8950 (4) nm, b=1.3753 (7) nm, c=1.8650 (9) Nm, α=β=γ=90 °, z=4, v=2.296 (2) nm3, dc=1.508 mg m-3, m (mok α)=1.145 mm-1, f(000) = 1048.

The ALPHA-ketobutyric acid of the present invention is structurally characterized in that to methoxybenzoyl hydrazone stannous phenide coordination compound: stannum in molecule Atom is hexa-coordinate distorted octahedron configuration.

The ALPHA-ketobutyric acid of the present invention has certain thermally-stabilised scope to methoxybenzoyl hydrazone stannous phenide coordination compound, Can stable existence below 244 DEG C.

As a second aspect of the present invention a kind of ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound Preparation method, adds diphenyl stannum dichloride, to methoxybenzoyl hydrazine, 2-butanone acid in the reaction vessel having nitrogen protection And solvent absolute methanol, react 5 ~ 24 h, cooling under conditions of temperature is 45 ~ 65 DEG C, filter, under conditions of 20 ~ 35 DEG C Control solvent volatilization crystallization, obtain yellow transparent crystal, as ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide coordination compound.

The ALPHA-ketobutyric acid of the present invention to the preparation characteristic of methoxybenzoyl hydrazone stannous phenide coordination compound is: from letter relatively The raw material being singly easy to get sets out, and without the separation of intermediate, directly obtains baroque molecule, i.e. one kettle way;Such reaction Economically and environmentally on close friend advantageously.

In a preferred embodiment of the invention, described diphenyl stannum dichloride, to methoxybenzoyl hydrazine, 2-butanone The amount of the material of sour three is than for 1:(1 ~ 1.05): (1.05 ~ 1.15).

In a preferred embodiment of the invention, described solvent absolute methanol consumption is every mM of diphenyl dichloride Stannum adds 15 ~ and 35 milliliters.

A kind of ALPHA-ketobutyric acid as a third aspect of the present invention exists to methoxybenzoyl hydrazone stannous phenide coordination compound Prepare the application in cancer therapy drug.

Applicant has carried out external anticancer and has lived to above-mentioned ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound Property determine research it is thus identified that ALPHA-ketobutyric acid has certain Anti-cancer biologic to methoxybenzoyl hydrazone stannous phenide coordination compound lives Property, that is to say, that the purposes of above-mentioned coordination compound is the application in preparing cancer therapy drug, is exactly specifically to prepare anti-human lung Application in cancer, human liver cancer and human breast carcinoma medicine.

The ALPHA-ketobutyric acid of the present invention is thin to human lung carcinoma cell, human liver cancer to methoxybenzoyl hydrazone stannous phenide coordination compound Born of the same parents and human breast cancer cell show good active anticancer, and the ALPHA-ketobutyric acid of the present invention is to methoxybenzoyl hydrazone diphenyl The features such as stannum coordination compound active anticancer height, low cost, preparation method are simple, the cancer therapy drug for developing new provides new way.

Brief description

Fig. 1 is the ir spectrogram to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid.

Fig. 2 is ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound1H nmr spectrogram.

Fig. 3 is ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound13C nmr spectrogram.

Fig. 4 is ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound119Sn nmr spectrogram.

Fig. 5 is the crystal structure figure to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid.

Fig. 6 is the tg-dtg curve to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid.

Specific embodiment

By detailed description below, the present invention is described in further detail.

Embodiment 1:

The preparation to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid:

0.344g (1.0mmol) diphenyl stannum dichloride, 0.166g is added in the 100ml there-necked flask having nitrogen protection (1.0mmol) to methoxybenzoyl hydrazine, the acid of 0.112g (1.1mmol) 2-butanone and 15ml solvent absolute methanol, in temperature it is 8 h are reacted under conditions of 45 ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow transparent Crystal, as ALPHA-ketobutyric acid are to methoxybenzoyl hydrazone stannous phenide coordination compound.Yield: 84.6%.Fusing point: 244 ~ 246 DEG C (dec).

Elementary analysiss (c24h22n2o4Sn): value of calculation: c 55.13, h 4.25, n 5.38;Measured value: c 55.16, h 4.27, n 5.40.

ft-ir (kbr, ν/cm-1): 3448, 3047, 2964, 2929,1633, 1600, 1581, 1494, 1176, 1095, 846, 731, 684, 640, 603, 588, 513, 445, 422.

1h nmr (500 mhz, cdcl3, δ/ppm): 8.31 (d,j=8.7 hz, 2h), 7.80-7.82 (m, 4h), 7.45-7.46 (m, 6h), 7.01 (d,j=8.7 hz, 2h), 3.90 (s, 3h), 3.07-3.12 (q,j=7.5 hz, 2h), 1.30 (t,j=7.5 hz, 3h).

13c nmr (126 mhz, cdcl3, δ/ppm): 174.48, 163.53, 158.75, 136.15, 135.84, 131.36, 130.79, 129.36, 124.59, 113.87, 55.51, 21.09, 10.66.

119sn nmr (187 mhz, cdcl3, δ/ppm): -294.23.

Crystallographic data: rhombic system, space group p2 (1) 2 (1) 2 (1), a=0.8950 (4) nm, b=1.3753 (7) nm, c=1.8650 (9) nm, α=β=γ=90 °, z=4, v=2.296 (2) nm3, dc=1.508 mg m-3, m (mok α)=1.145 mm-1, f (000)=1048.

Embodiment 2:

The preparation to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid:

0.344g (1.0mmol) diphenyl stannum dichloride, 0.166g is added in the 100ml there-necked flask having nitrogen protection (1.0mmol) to methoxybenzoyl hydrazine, the acid of 0.107g (1.05mmol) 2-butanone and 35ml solvent absolute methanol, in temperature For reacting 5 h under conditions of 45 ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow saturating Bright crystal, as ALPHA-ketobutyric acid are to methoxybenzoyl hydrazone stannous phenide coordination compound.Yield: 83.4%.Fusing point: 244 ~ 246 DEG C (dec).

Elementary analysiss (c24h22n2o4Sn): value of calculation: c 55.13, h 4.25, n 5.38;Measured value: c 55.16, h 4.27, n 5.40.

ft-ir (kbr, ν/cm-1): 3448, 3047, 2964, 2929,1633, 1600, 1581, 1494, 1176, 1095, 846, 731, 684, 640, 603, 588, 513, 445, 422.

1h nmr (500 mhz, cdcl3, δ/ppm): 8.31 (d,j=8.7 hz, 2h), 7.80-7.82 (m, 4h), 7.45-7.46 (m, 6h), 7.01 (d,j=8.7 hz, 2h), 3.90 (s, 3h), 3.07-3.12 (q,j=7.5 hz, 2h), 1.30 (t,j=7.5 hz, 3h).

13c nmr (126 mhz, cdcl3, δ/ppm): 174.48, 163.53, 158.75, 136.15, 135.84, 131.36, 130.79, 129.36, 124.59, 113.87, 55.51, 21.09, 10.66.

119sn nmr (187 mhz, cdcl3, δ/ppm): -294.23.

Crystallographic data: rhombic system, space group p2 (1) 2 (1) 2 (1), a=0.8950 (4) nm, b=1.3753 (7) nm, c=1.8650 (9) nm, α=β=γ=90 °, z=4, v=2.296 (2) nm3, dc=1.508 mg m-3, m (mok α)=1.145 mm-1, f (000)=1048.

Embodiment 3:

The preparation to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid:

0.344g (1.0mmol) diphenyl stannum dichloride, 0.174g is added in the 100ml there-necked flask having nitrogen protection (1.05mmol) to methoxybenzoyl hydrazine, the acid of 0.117g (1.15mmol) 2-butanone and 25ml solvent absolute methanol, in temperature For reacting 24 h under conditions of 45 ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow Transparent crystal, as ALPHA-ketobutyric acid are to methoxybenzoyl hydrazone stannous phenide coordination compound.Yield: 83.6%.Fusing point: 244 ~ 246 ℃(dec).

Elementary analysiss (c24h22n2o4Sn): value of calculation: c 55.13, h 4.25, n 5.38;Measured value: c 55.16, h 4.27, n 5.40.

ft-ir (kbr, ν/cm-1): 3448, 3047, 2964, 2929,1633, 1600, 1581, 1494, 1176, 1095, 846, 731, 684, 640, 603, 588, 513, 445, 422.

1h nmr (500 mhz, cdcl3, δ/ppm): 8.31 (d,j=8.7 hz, 2h), 7.80-7.82 (m, 4h), 7.45-7.46 (m, 6h), 7.01 (d,j=8.7 hz, 2h), 3.90 (s, 3h), 3.07-3.12 (q,j=7.5 hz, 2h), 1.30 (t,j=7.5 hz, 3h).

13c nmr (126 mhz, cdcl3, δ/ppm): 174.48, 163.53, 158.75, 136.15, 135.84, 131.36, 130.79, 129.36, 124.59, 113.87, 55.51, 21.09, 10.66.

119sn nmr (187 mhz, cdcl3, δ/ppm): -294.23.

Crystallographic data: rhombic system, space group p2 (1) 2 (1) 2 (1), a=0.8950 (4) nm, b=1.3753 (7) nm, c=1.8650 (9) nm, α=β=γ=90 °, z=4, v=2.296 (2) nm3, dc=1.508 mg m-3, m (mok α)=1.145 mm-1, f (000)=1048.

Embodiment 4:

The preparation to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid:

3.440g (10.0mmol) diphenyl stannum dichloride, 1.710g is added in the 500ml there-necked flask having nitrogen protection (10.3mmol) to methoxybenzoyl hydrazine, the acid of 1.122g (11.0mmol) 2-butanone and 200ml solvent absolute methanol, in temperature Spend for reacting 22 h under conditions of 45 ~ 65 DEG C, cooling, filter, control solvent volatilization crystallization under conditions of 20 ~ 35 DEG C, obtain yellow Color transparent crystal, as ALPHA-ketobutyric acid are to methoxybenzoyl hydrazone stannous phenide coordination compound.Yield: 81.7%.Fusing point: 244 ~ 246℃(dec).

Elementary analysiss (c24h22n2o4Sn): value of calculation: c 55.13, h 4.25, n 5.38;Measured value: c 55.16, h 4.27, n 5.40.

ft-ir (kbr, ν/cm-1): 3448, 3047, 2964, 2929,1633, 1600, 1581, 1494, 1176, 1095, 846, 731, 684, 640, 603, 588, 513, 445, 422.

1h nmr (500 mhz, cdcl3, δ/ppm): 8.31 (d,j=8.7 hz, 2h), 7.80-7.82 (m, 4h), 7.45-7.46 (m, 6h), 7.01 (d,j=8.7 hz, 2h), 3.90 (s, 3h), 3.07-3.12 (q,j=7.5 hz, 2h), 1.30 (t,j=7.5 hz, 3h).

13c nmr (126 mhz, cdcl3, δ/ppm): 174.48, 163.53, 158.75, 136.15, 135.84, 131.36, 130.79, 129.36, 124.59, 113.87, 55.51, 21.09, 10.66.

119sn nmr (187 mhz, cdcl3, δ/ppm): -294.23.

Crystallographic data: rhombic system, space group p2 (1) 2 (1) 2 (1), a=0.8950 (4) nm, b=1.3753 (7) nm, c=1.8650 (9) nm, α=β=γ=90 °, z=4, v=2.296 (2) nm3, dc=1.508 mg m-3, m (mok α)=1.145 mm-1, f (000)=1048.

Test example:

To methoxybenzoyl hydrazone stannous phenide coordination compound, it is to pass through that its Anticancer Activity in vitro measures to the ALPHA-ketobutyric acid of the present invention Mtt experimental technique is realized.

Mtt analytic process:

With metabolism reduction 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide it is Basis.Succinate dehydrogenase in living cells mitochondria can make exogenous mtt be reduced to water-insoluble bluish violet crystallization first a ceremonial jade-ladle, used in libation (formazan) and be deposited in cell, and dead cell no this function.Dimethyl sulfoxide (dmso) can dissolve the first a ceremonial jade-ladle, used in libation in cell, Measure the optical density of characteristic wavelength with microplate reader, can indirectly reflect living cells quantity.

The ALPHA-ketobutyric acid of embodiment 1 preparation is measured to methoxybenzoyl hydrazone stannous phenide coordination compound using mtt method Inhibitory activity to human lung carcinoma cell (h460), human liver cancer cell (hepg2) and human breast cancer cell (mcf7).

Cell strain and cultivating system: h460, hepg2 and mcf7 cell strain takes from American. tissue incubator (atcc).With containing Rpmi 1640 (gibico company) culture medium of 10% hyclone, in 5% (volume fraction) co2, 37 DEG C of saturated humidity incubators Inside carry out In vitro culture.

Test process: test medicinal liquid (1nm ~ 10 μm) is added separately in each hole according to the Concentraton gradient of concentration, often Individual concentration sets 6 parallel holes.Experiment is divided into drug study group (being separately added into the test medicine of variable concentrations), matched group (only to add training Nutrient solution and cell, are not added with testing medicine) and blank group (only adding culture medicine, be not added with cell and test medicine).Orifice plate after dosing is put In 37 DEG C, 5%co272h is cultivated in incubator.The activity of control drug measures according to the method for test sample.Cultivating 72h In orifice plate afterwards, every hole adds mtt 40 μ l (being made into 4mg/ml with d-hanks buffer).After placing 4h at 37 DEG C, remove upper strata Clear liquid.Every hole adds 150 μ l dmso, vibrates 5min, makes formazan crystallize dissolving.Finally, using automatic microplate reader in 570nm The optical density in each hole is detected at wavelength.

Data processing: data processing uses graph pad prism version 7.0 program, coordination compound ic50By journey The nonlinear regression model (NLRM) in sequence with s shape dose response is fitted obtaining.

Thin to human lung carcinoma cell (h460), human liver cancer cell (hepg2) and human breast cancer cell (mcf7) with mtt analytic process Born of the same parents' strain is analyzed, and measures its ic50Value, as shown in table 1, conclusion is result: from data in table, with the 2- carbonyl of the present invention Butanoic acid is used as cancer therapy drug to methoxybenzoyl hydrazone stannous phenide coordination compound, to human lung carcinoma cell (h460), human liver cancer cell (hepg2) and human breast cancer cell (mcf7) has certain drug effect, can be used as the candidate compound of cancer therapy drug.

Table 1 ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide coordination compound cancer therapy drug external activity test data.

Human lung cancer Human liver cancer Human breast carcinoma Cell strain h460 hepg2 mcf7 ic50(μm) 1.67±0.10 2.03±0.19 1.34±0.22

Remaining embodiment preparation ALPHA-ketobutyric acid to methoxybenzoyl hydrazone stannous phenide coordination compound with mtt method to people's lung The same test example of active anticancer method of testing of cancerous cell (h460), human liver cancer cell (hepg2) and human breast cancer cell (mcf7), Test result is essentially identical with table 1.

These are only the preferred embodiments of the present invention and test example, be not limited to the present invention it is clear that the skill of this area Art personnel can carry out various changes, modification without departing from the spirit and scope of the present invention to the present invention.If to the present invention's These modifications and modification belong within the scope of the claims in the present invention and its equivalent technologies, belong to the protection model of the present invention Enclose.

Claims (9)

1. a kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide coordination compound, for the coordination compound of following structural formula (i):
(i)
Wherein r is phenyl.
2. contain a kind of ALPHA-ketobutyric acid as claimed in claim 1 to methoxybenzoyl hydrazone stannous phenide coordination compound, it is red External spectrum data: ft-ir (kbr, ν/cm-1): 3448, 3047, 2964, 2929,1633, 1600, 1581, 1494, 1176, 1095, 846, 731, 684, 640, 603, 588, 513, 445, 422;Its nuclear-magnetism modal data:1h nmr (500 mhz, cdcl3, δ/ppm): 8.31 (d,j=8.7 hz, 2h), 7.80-7.82 (m, 4h), 7.45- 7.46 (m, 6h), 7.01 (d,j=8.7 hz, 2h), 3.90 (s, 3h), 3.07-3.12 (q,j=7.5 hz, 2h), 1.30 (t,j=7.5 hz, 3h);13c nmr (126 mhz, cdcl3, δ/ppm): 174.48, 163.53, 158.75, 136.15, 135.84, 131.36, 130.79, 129.36, 124.59, 113.87, 55.51, 21.09, 10.66;119sn nmr (187 mhz, cdcl3, δ/ppm): -294.23.
3. ALPHA-ketobutyric acid as claimed in claim 1 is to methoxybenzoyl hydrazone stannous phenide coordination compound, wherein, described ALPHA-ketobutyric acid is crystal structure to methoxybenzoyl hydrazone stannous phenide coordination compound, and its crystallographic data is as follows: rhombic system, Space group p2 (1) 2 (1) 2 (1), a=0.8950 (4) nm, b=1.3753 (7) nm, c=1.8650 (9) nm, α=β =γ=90 °, z=4, v=2.296 (2) nm3, dc=1.508 mg m-3, m (mok α)=1.145 mm-1, f (000)= 1048;In molecule, tin atom is hexa-coordinate distorted octahedron configuration.
4. ALPHA-ketobutyric acid described in claim 1 has certain thermally-stabilised model to methoxybenzoyl hydrazone stannous phenide coordination compound Enclose, can stable existence below 244 DEG C.
5. the preparation method to methoxybenzoyl hydrazone stannous phenide coordination compound for the ALPHA-ketobutyric acid described in claim 1, it is special Levy is to add diphenyl stannum dichloride, sour and molten to methoxybenzoyl hydrazine, 2-butanone in the reaction vessel having nitrogen protection Agent absolute methanol, reacts 5 ~ 24 h, cooling under conditions of temperature is 45 ~ 65 DEG C, filters, control under conditions of 20 ~ 35 DEG C Solvent volatilization crystallization, obtains yellow transparent crystal, as ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide coordination compound.
6. preparation as claimed in claim 5 method it is characterised in that described diphenyl stannum dichloride, to methoxybenzene first Hydrazides, the amount ratio of the material of 2-butanone acid three are for 1:(1 ~ 1.05): (1.05 ~ 1.15).
7. the method for preparation as claimed in claim 5 is it is characterised in that described solvent absolute methanol consumption is every mM two Phenyl dichloro stannum adds 15 ~ and 35 milliliters.
8. ALPHA-ketobutyric acid described in claim 1 is being prepared in cancer therapy drug to methoxybenzoyl hydrazone stannous phenide coordination compound Application.
9. the application described in claim 8, wherein said cancerous cell is human lung carcinoma cell, human liver cancer cell, human breast cancer cell.
CN201610753673.3A 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide complex and its preparation method and application CN106366120B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610753673.3A CN106366120B (en) 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide complex and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610753673.3A CN106366120B (en) 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide complex and its preparation method and application

Publications (2)

Publication Number Publication Date
CN106366120A true CN106366120A (en) 2017-02-01
CN106366120B CN106366120B (en) 2019-02-19

Family

ID=57903913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610753673.3A CN106366120B (en) 2016-08-30 2016-08-30 A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide complex and its preparation method and application

Country Status (1)

Country Link
CN (1) CN106366120B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237562A (en) * 2015-11-11 2016-01-13 衡阳师范学院 2-oxo propionic acid salicyloyl hydrazone tin diphenyl complex and preparation method and application thereof
CN105348318A (en) * 2015-11-11 2016-02-24 衡阳师范学院 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications
CN105399764A (en) * 2015-11-11 2016-03-16 衡阳师范学院 2-oxo-propionic acid benzoyl hydrazone dibenzyl tin complex as well as preparation method and application thereof
CN105646568A (en) * 2016-04-11 2016-06-08 衡阳师范学院 2-oxo-propionic acid salicyloyl hydrazone diphenyltin complex as well as preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237562A (en) * 2015-11-11 2016-01-13 衡阳师范学院 2-oxo propionic acid salicyloyl hydrazone tin diphenyl complex and preparation method and application thereof
CN105348318A (en) * 2015-11-11 2016-02-24 衡阳师范学院 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications
CN105399764A (en) * 2015-11-11 2016-03-16 衡阳师范学院 2-oxo-propionic acid benzoyl hydrazone dibenzyl tin complex as well as preparation method and application thereof
CN105646568A (en) * 2016-04-11 2016-06-08 衡阳师范学院 2-oxo-propionic acid salicyloyl hydrazone diphenyltin complex as well as preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《ACGC CHEMICAL RESEARCH COMMUNICATIONS》 *

Also Published As

Publication number Publication date
CN106366120B (en) 2019-02-19

Similar Documents

Publication Publication Date Title
Shanker et al. Ru (II) complexes of N4 and N2O2 macrocyclic Schiff base ligands: Their antibacterial and antifungal studies
Ramesh et al. Synthesis, spectral and antifungal activity of Ru (II) mixed‐ligand complexes
Thirumavalavan et al. Synthesis of lateral macrobicyclic compartmental ligands: structural, magnetic, electrochemical, and catalytic studies of mono-and binuclear copper (II) complexes
Li et al. A nine-coordinated bismuth (III) complex derived from pentadentate 2, 6-diacetylpyridine bis (4 N-methylthiosemicarbazone): crystal structure and both in vitro and in vivo biological evaluation
Corrêa et al. Ruthenium (II) complexes of 1, 3-thiazolidine-2-thione: Cytotoxicity against tumor cells and anti-Trypanosoma cruzi activity enhanced upon combination with benznidazole
Parish et al. Chemical and biological studies of dichloro (2-((dimethylamino) methyl) phenyl) gold (III)
Shafaatian et al. Synthesis, crystal structure, fluorescence and electrochemical studies of a new tridentate Schiff base ligand and its nickel (II) and palladium (II) complexes
Panchal et al. Bactericidal activity of different oxovanadium (IV) complexes with Schiff bases and application of chelation theory
Ferreira et al. Synthesis, characterization and antifungal activity of new dithiocarbamate-based complexes of Ni (II), Pd (II) and Pt (II)
Li et al. Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chlorobenzohydroxamato) tin (IV) chloride
CN103396436B (en) Monobutyltin substituted salicylic aldehydes contracting arylamine Schiff base complex and preparation method and application
CN102060869A (en) Tindiphenyl (IV) coordination compound of benzoylformic acid-3-hydroxyl-2-naphthyl formyl hydrazone as well as preparation method and application thereof
CN101838284B (en) Dibutyltin oxide coordination compound and preparation method and application thereof
Sedaghat et al. Synthesis and spectroscopic studies of new organotin (IV) complexes with tridentate N-and O-donor Schiff bases
Manna et al. New insights on the active species and mechanism of cytotoxicity of salan-Ti (IV) complexes: A stereochemical study
Guo et al. Stereoselective formation of seven-coordinate titanium (IV) monomer and dimer complexes of ethylenebis (o-hydroxyphenyl) glycine
Hussain et al. Synthesis, characterization, biological activities, crystal structure and DNA binding of organotin (IV) 5-chlorosalicylates
Ghaffari et al. Crystal structure, electrochemistry, and catalytic studies of a series of new oxidovanadium (IV) Schiff-base complexes derived from 1, 2-diphenyl-1, 2-ethylenediamine
Cotton et al. The lengths of molybdenum to molybdenum quadruple bonds: Correlations, explanations, and corrections
Friebolin et al. Antitumoral activity of non-platinum xanthate complexes
CN105198921B (en) A kind of 2- carbonyl -2- phenylacetic acid salicyloyl hydrazone dibutyl tin complex and its preparation method and application
Naseri et al. First row transition metal complexes of thienyl substituted terpyridine: Structural, photophysical and biological studies
Mondal et al. Synthesis, structure and solution chemistry of dioxidovanadium (V) complexes with a family of hydrazone ligands. Evidence of formation of centrosymmetric dimers via H-bonds in the solid state
Khan et al. Observation of π-hole interactions in the solid state structures of three new copper (II) complexes with a tetradentate N4 donor Schiff base: Exploration of their cytotoxicity against MDA-MB 468 cells
Yin et al. Synthesis and crystal structure of two new Bi (III) complexes {(Me2NCS2) 3Bi} 2 and {[(CH2) 5NCS2] 2BiI} 2

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant